About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

The toll-free dial-in number for participants is 1 - 800 - 715 - 9871, conference ID: 1503863 . A webcast of the call will be accessible via Sienna's website. The webcast of the call will be available ...

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key ...

Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat ...

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).

Verrica recognized collaboration revenue of $0.1 million for the three months ended September 30, 2024 related to the Collaboration and License Agreement (the “Torii Agreement”) with Torii ...

In addition, on November 4, 2024, Amwell made a grant of RSUs covering 5,084 shares of its Class A common stock to two new employees. The grants were offered as material inducement to the employees’ ...

Total revenues were $175.7 million in the third quarter of 2024, an increase of 14% compared to the same period in 2023. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non ...

Experience Empower 2024’s best moments here: https://www.inovalon.com/empower/.

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...

Strong balance sheet with cash, cash equivalents, and marketable securities of $267.4 million as of September 30, 2024, provides cash runway into 2027 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) ...

COPENHAGEN, DENMARK and BOSTON, MA, USA, November 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the ...